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ABSTRACT
Patients with Diamond-Blackfan anemia (DBA) who are unresponsive to or intolerant of corticosteroids,
experience treatment failure with other treatments, develop additional cytopenias or clonal disease, or opt for
curative therapy are often treated with allogeneic bone marrow transplantation. We studied the transplantation
outcomes of 61 DBA patients whose data were reported to the International BoneMarrow Transplant Registry
between 1984 and 2000. The median age was 7 years (range, 1-32 years). Among 55 patients with available
transfusion information, 35 (64%) had received>20 units of blood before transplantation. Most patients (67%)
received their bone marrow grafts from an HLA-matched related donor. The median time to neutrophil
recovery was 17 days (range, 10-119 days) and to platelet recovery was 23 days (range, 9-119 days). Five patients
did not achieve neutrophil engraftment. The 100-day mortality was 18% (95% confidence interval, 10%-29%).
Grade II to IV acute graft-versus-host disease occurred in 28% (range, 17%-39%) and chronic graft-versus-
host disease in 26% (range, 15%-39%). The 3-year probability of overall survival was 64% (range, 50%-74%).
In univariate analysis, a Karnofsky score >90 and transplantation from an HLA-identical sibling donor were
associated with better survival. These data suggest that allogeneic bone marrow transplantation is effective for
the treatment of DBA. Transplantation before deterioration of the performance status and from an HLA-
identical sibling donor may improve survival.
© 2005 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
Diamond-Blackfan anemia (DBA) is a rare, con-
enital, pure red cell aplasia caused by an intrinsic
rythroid regenerative defect [1,2]. The molecular
vent responsible for this single lineage defect is not
ompletely known in all patients. Approximately 25%
f cases are associated with a mutation in ribosomal
rotein RPS19 that results in RPS19 protein haploin-
ufﬁciency [3,4]. Because there are no clear correla-
ions between the mutated RPS19 and the clinical A
00henotype, even within a multiplex family, it is likely
hat additional molecular events collaborate for the
evelopment of this disease [5,6].
DBA is predominantly a disease of childhood.
linical features of DBA include normocytic or mac-
ocytic anemia, reticulocytopenia, and bone marrow
rythrocytopenia. The natural history of DBA is vari-
ble; although approximately 20% of patients may
ecome transfusion or corticosteroid independent,
ost will eventually require long-term treatment [7].
pproximately 80% of patients have an initial re-
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Bponse to corticosteroids [8]. Other agents—such as
ndrogens, cyclosporine, intravenous gamma globu-
in, metoclopramide, or erythropoietin—have been
sed with limited success in steroid-refractory patients
9-14]. Patients unresponsive to or unable to tolerate
edical therapies require chronic red cell transfusions
nd are at risk for iron overload, with its consequent
omplications.
Allogeneic bone marrow transplantation (BMT) is
potentially curative treatment option for DBA. Since
he ﬁrst report in 1976 of correction of hematopoiesis
fter BMT, several authors have reported successful
ransplantation for selected patients with DBA [15-
2]. However, these reports are limited by small num-
ers of patients. The largest report to date, from the
iamond-Blackfan Anemia Registry, had 20 patients.
e analyzed the data reported to the International
one Marrow Transplant Registry (IBMTR) to deter-
ine outcomes after HLA-matched related (n  41)
nd alternative donor (n  20) BMT in 61 patients
ith DBA. This is the largest body of experience on
llogeneic transplantation outcomes in this disease.
ATIENTS AND METHODS
ata Sources
The IBMTR is a voluntary working group of more
han 400 transplant centers worldwide that contribute
etailed data on consecutive allogeneic hematopoietic
tem cell transplantations to a statistical center at the
ealth Policy Institute of the Medical College of
isconsin in Milwaukee. On the basis of data col-
ected in the Centers for Disease Control Hospital
urveys and US Government Accounting Ofﬁce and
orldwide surveys of transplantation activity, approx-
mately 40% of allogeneic transplantations worldwide
re registered with the IBMTR. Participating centers
re required to report all transplantations consecu-
ively; compliance is monitored by on-site audits. Pa-
ients are followed up longitudinally, with yearly fol-
ow-up.
The IBMTR collects data at 2 levels: registration
nd research. Registration data include disease type,
ge, sex, pretransplantation disease stage and chemo-
herapy responsiveness, date of diagnosis, graft type
bone marrow, blood-derived stem cells, or cord
lood), pretransplantation conditioning regimen,
osttransplantation disease progression and survival,
evelopment of a new malignancy, and cause of death.
articipating transplant centers register consecutive
ransplantations. Research data are collected on a sub-
et of registered patients selected by using a weighted
andomization scheme and include detailed disease
nd pretransplantation and posttransplantation clini-
al information. Computerized checks for errors, phy-
ician reviews of submitted data, and on-site audits of P
B & M Tarticipating centers ensure the quality of data. Ob-
ervational studies conducted by the IBMTR are per-
ormed with a waiver of informed consent and in
ompliance with Health Insurance Portability and Ac-
ountability Act regulations as determined by the In-
titutional Review Board and the Privacy Ofﬁcer of
he Medical College of Wisconsin.
atients
Ninety-three patients were registered as having
eceived a transplant between 1984 and 2000. Of
hese, comprehensive patient, disease, and transplan-
ation characteristics were available on 61 (66%) of 93
atients. The diagnosis of DBA was reported by the
ransplant center, and the decision to proceed to
ransplantation was at the discretion of the transplant
enter. Patient, disease, and transplant characteristics
nd overall survival of those with or without compre-
ensive data were similar (overall survival at 3 years,
3% [range, 53%-73%] versus 64% [range, 50%-
4%]; P .93). Eligible cases came from 37 reporting
eams from 17 countries. The median follow-up of
urvivors was 126 months (range, 12-164 months).
nd Points
Primary end points were neutrophil and platelet
ecovery, 100-day mortality, acute and chronic graft-
ersus-host disease (GVHD), and overall survival. He-
atopoietic recovery was deﬁned as achieving an ab-
olute neutrophil count 0.5  109/L for 3
onsecutive days and platelets 20  109/L (untrans-
used). Acute and chronic GVHD were deﬁned as
rade II to IV acute GVHD and any chronic GVHD
limited or extensive), respectively [23,24]. For analy-
es of overall survival, failure was death from any
ause; surviving patients were censored at the date of
ast contact.
tatistical Analysis
The probabilities of neutrophil and platelet recov-
ry and acute and chronic GVHD were calculated by
sing cumulative incidence rates to accommodate
ompeting risks; probabilities of day 100 mortality and
verall survival were calculated by using the Kaplan-
eier estimator [25,26]. Estimates of standard error
or the survival function were calculated by Green-
ood’s formula, and 95% conﬁdence intervals (CI)
ere calculated by using log-transformed intervals
27]. Assessment of potential prognostic factors for
urvival was limited to univariate analysis because of
he small sample size. Table 1 shows variables consid-
red in univariate analysis. Variables not listed in the
nal analysis did not meet the 5% level of signiﬁcance.
values for differences in outcomes between groups
ere calculated by using the point-wise estimator. All
values are 2 sided. All computations were performed
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6y using the statistical package SAS version 8.0 (SAS
nstitute, Cary, NC).
ESULTS
atient Characteristics
Patient-, disease-, and treatment-related charac-
eristics are summarized in Table 2. The median age
t transplantation was 7 years (range, 1-32 years).
wenty-ﬁve (41%) of 61 patients were male. Most
atients (68%) had a pretransplantation Karnofsky
erformance score of 90 or 100. Most (93%) had
eceived steroids, and 48% had received additional
herapies before transplantation. Among the 55 pa-
ients with available information on transfusions, 28
atients (51%) received 1 to 50 transfusions, and 27
49%) received50 transfusions. All patients received
one marrow grafts.
Of the 61 patients in this study, 46 (75%) under-
ent transplantation after 1989. The registry data on
ransplantation outcomes in 10 patients with DBA
1984 to 1990) have previously been reported [17].
wo patients included in this article who underwent
ransplantation in 1990 were also included in the pre-
ious article. Forty-one patients (67%) received trans-
lants from an HLA-identical sibling donor, 8 (13%)
rom a nonsibling family donor, and 12 (20%) from a
atched unrelated donor. Patients underwent trans-
lantation a median of 62 months after diagnosis
range, 5-286 months). All patients except 1 in this
eries received conventional, cyclophosphamide-based
onditioning regimens. Only 18% of patients received
otal body irradiation. The median number of mono-
uclear cells transplanted per kilogram recipient
eight was 4  108/kg (range, 1-12  108/kg). Cy-
losporin A and methotrexate were the most fre-
uently used agents for GVHD prophylaxis. Approx-
mately one quarter of patients started hematopoietic
rowth factors within 7 days after transplantation.
able 1. Variables Considered in the Univariate Analysis
atient-related variables
Age at transplantation: <10 vs. >10 y
Sex: female vs. male
Karnofsky performance score at transplantation: <90 vs. >90
isease-related variables
Number of transfusions before transplantation: <20 vs. >20
TBI for conditioning regimen: yes vs. no
Nucleated cell dose: <4  108/kg vs. >4  108/kg
Time from diagnosis to transplantation: <60 vs. >60 mo
reatment-related variables
Donor-recipient sex match: F-M vs. others
Donor-recipient CMV status: donor-recipient negative vs.
others
Type of donor: HLA-identical sibling vs. others
Year of transplantation: <1990 vs. >1990
Growth factors after transplantation: yes vs. noatients who received an alternative donor transplant
02ere more likely to be older (9 versus 5 years; P 
03), to have had a longer median time from diagnosis
o transplantation (110 versus 58 months; P  .02),
nd to have received total body irradiation as part of
he conditioning regimen (45% versus 5%; P  .001).
utcomes
Hematopoietic recovery. Fifty-four of 59 evaluable
atients achieved neutrophil recovery. Among those
ho achieved neutrophil recovery, the median time to
ecovery was 17 days (range, 10-119 days). The prob-
bility of neutrophil recovery at day 100 was 90%
95% CI, 81%-95%) after transplantation from any
onor (Table 3). Among patients who were heavily
ransfused (50 transfusions) before BMT, the prob-
bility of neutrophil recovery at day 28 was lower
67% [95% CI, 46%-85%] versus 89% [95% CI,
1%-95%]; P  .04). However, by days 60 and 100,
here were no signiﬁcant differences between groups.
he characteristics of the 5 patients who did not
chieve neutrophil recovery did not differ from those
f patients who achieved recovery (ie, age, number of
ransfusions before BMT, interval from diagnosis to
MT, donor type, donor-recipient ABO compatibil-
ty, and cell dose). The median time for platelet re-
overy was 23 days (range, 9-119 days). Fifty-one
ercent of patients achieved platelet recovery at 28
ays after transplantation, and 75% achieved platelet
ecovery at 100 days. The tempo of platelet recovery
mong heavily transfused patients was slower. Even
hough recovery rates were not statistically different at
8 and 100 days after transplantation, at 60 days, the
roportion of patients with platelet recovery was sig-
iﬁcantly higher in patients who had received50 red
lood cell transfusions compared with those who re-
eived50 red blood cell transfusions (85% [95% CI,
1%-95%] versus 63% [95% CI, 44%-79%]; P 
04).
Graft-versus-host disease. The cumulative incidence
f grade II to IV acute GVHD was 28% (95% CI,
7%-39%) (Table 3). There were no differences in
he incidence of acute GVHD by donor type. The
umulative incidence of chronic GVHD at 3 years was
ower among recipients of HLA-identical sibling do-
or grafts compared with recipients of other donor
rafts (18% [95% CI, 7%-32%] vs 51% [95% CI,
6%-77%]; P  .03). The number of patients who
eceived unrelated or mismatched related grafts was
oo small to meaningfully evaluate whether the risk of
cute or chronic GVHD was higher in these patients
ompared with patients who received matched related
onor transplants. Chronic GVHD occurred in 19%
95% CI, 9%-28%), 26% (95% CI, 15%-39%), and
9% (95% CI, 17%-43%) of patients at 1, 3, and 5
ears, respectively (Table 3).Survival and disease response. The probabilities of
TN
A
A
M
K
P
N
C
N
N
D
D
D
D
T
T
Y
G
G
B
D
*
†
‡
§

¶
#
BMT for Diamond-Blackfan Anemia
Bable 2. Characteristics of Patients Who Underwent Allogeneic Bone Marrow Transplantation for Diamond-Blackfan Anemia until 2000
Patient Characteristics No. Evaluable Data
o. patients 61
ge, y, median (range) 61 7 (1–32)
ge >10 y 61 20 (33)
ale sex 61 25 (41)
arnofsky score >90 60 41 (68)
retransplantation therapy 60
None 4 (7)
Steroids alone 27 (45)
Steroids  other* 29 (48)
o. of transfusions before transplantation 55
1–20 20 (36)
21–50 8 (15)
>50 27 (49)
onditioning regimen 61
BuCy  other 44 (72)
CyRad  other 13 (21)
Other† 4 (7)
ucleated cell dose, 108/kg, median (range) 56 4 (1–12)
ucleated cell dose >4  108/kg 56 25 (45)
onor-recipient sex match‡ 59
M-M 16 (27)
M-F 13 (22)
F-M 9 (15)
F-F 21 (36)
onor-recipient CMV status 50
/ 19 (38)
/ 6 (12)
/ 5 (10)
/ 20 (40)
onor-recipient ABO compatibility§ 53
Match 27 (51)
Minor mismatch 10 (19)
Major mismatch 10 (19)
Bidirectional mismatch 6 (11)
onor type 61
HLA-identical sibling 41 (67)
Other relative 8 (13)
Unrelated¶ 12 (20)
ime from diagnosis to transplantation, mo, median (range) 61 62 (5–286)
ime from diagnosis to transplantation >60 mo 61 33 (54)
ear of transplantation 61
<1989 15 (25)
1990–1995 24 (39)
1996–2000 22 (36)
VHD prophylaxis# 61
None 2 (3)
MTX  other 4 (7)
CsA  other 12 (20)
MTX  CsA  other 38 (62)
T-cell depletion  other 5 (8)
-CSF or GM-CSF given within 7 days after transplantation 61 14 (23)
u indicates busulfan; CsA, cyclosporine; Cy, cyclophosphamide; GVHD, graft-versus-host disease; MTX, methotrexate; CMV, cytomegalovirus;
G-CSF, granulocyte colony-stimulating factor; GM-GSF, granulocyte-macrophage colony-stimulating factor; Rad, combination of total body,
total lymph node, and total abdominal irradiation.
ata are n (%) unless otherwise marked.
Other pretransplantation therapies included cyclosporine, other immunosuppressive agents given alone, cytokines, cyclosporine  cytokines,
cyclosporine  cytokines  intravenous immunoglobulin, antithymocyte globulin (ATG), ATG  cytokines, ATG  other immunosupressive
agents, ATG  cyclosporine, ATG  cyclosporine  cytokines, androgens, androgens  cytokines, and other combinations.
Other conditioning regimens were cyclophosphamide other (n 3) and total body irradiation (TBI) ﬂudarabine (n 1). Eleven (18%) of 61
received TBI as part of the conditioning regimen.
Two recipient-donor sex matches are unknown; however, they were a complete HLA match.
ABO compatibility: ABO matched  donor and recipient are the same ABO blood group; minor mismatch  donor with blood group O into
recipient with blood group A, B, or AB and donor with blood group A or B into recipient with blood group AB; major mismatch  donor with
blood group A, B, or AB into recipient with blood group O and donor with blood group AB into recipient with blood group A or B; bidirectional
 donor with blood group A into recipient with blood group B and donor with blood group B into recipient with blood group A.
Three in the “other relative” donor category were parents.
Unrelated donors were matched by using a serologic method for -A and -B and molecular typing for -DR.
Other GVHD prophylaxes were corticosteroids, ATG, anti–T-lymphocyte monoclonal antibody, and cyclosporine.
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6verall survival at 1 and 3 years after transplantation
ere 67% (95% CI, 54%-77%) and 63% (95% CI,
0%-74%), respectively (Table 3). A Karnofsky score
90 was associated with improved 100-day (93% ver-
us 63%; P  .01) and 3-year (75% versus 42%; P 
01) survival (Table 4 and Figure 1). Transplantation
rom an HLA-identical sibling donor (versus alterna-
ive donors) was also associated with improved overall
urvival at 1 and 3 years (78% versus 45% [P .01] and
6% versus 39% [P  .01], respectively; Figure 2). The
- and 3-year probability of overall survival of patients
ith a good performance status who received allografts
rom HLA-identical sibling donors (n  29) was 83%
95% CI, 67%-94%). The numbers of patients with
ther pairings of donor types and performance status
ere too few to make statistical comparisons.
Age at transplantation, patient and donor sex, sex
ismatch, patient-donor cytomegalovirus status, do-
or-recipient ABO compatibility, number of red
lood cell transfusions received before transplanta-
ion, time from diagnosis to transplantation, use of a
able 3. Transplantation Outcomes among Patients Who Underwent
llogeneic Transplantation for Diamond-Blackfan Anemia until 2000
Outcome
No.
Evaluable Data*
OD of the liver, n (%) 56 8 (14)
00-d mortality 61 18 (10–29)
ime to ANC >0.5  109/L,
median (range)† 54 17 (10–119)
NC >0.5  109/L 59
28 d 78 (66–86)
100 d 90 (80–95)
ime to platelets >20  109/L,
median (range) 55 23 (9–119)
latelets >20  109/L 55
28 d 51 (38–63)
100 d 75 (63–85)
cute GVHD at 100 d, grades II
to IV‡ 58 28 (17–39)
hronic GVHD§ 49
1 y 19 (9–28)
3 y 26 (15–39)
urvival 61
1 y 67 (54–77)
3 y 64 (50–74)
VHD indicates graft-versus-host disease; VOD, veno-occlusive
disease; ANC, absolute neutrophil count.
ata are probability (95% conﬁdence interval) % unless otherwise
marked.
The 100-day mortality was calculated with the 2 test. Probabilities
of acute GVHD, chronic GVHD, and engraftment were calcu-
lated by using the cumulative incidence estimate. Survival was
calculated by using the Kaplan-Meier product-limit estimate.
Among patients who achieved neutrophil recovery.
Patients are at risk for this event at 21 days after transplantation
with evidence of engraftment (2 patients were excluded).
Patients are at risk for this event at 90 days after transplantation
(12 patients were excluded).otal body irradiation–based conditioning regimen, n
04ucleated cell dose of the graft, year of transplanta-
ion, and use of growth factors after transplantation
ere not associated with survival. Additional analysis
sing lower and higher transfusion number cutoffs
10 versus 10 and 50 versus 50 units of blood)
lso failed to demonstrate a signiﬁcant survival differ-
nce (data not shown).
Of the 38 surviving patients with a median follow
p of 11 years (range, 1-14 years), 37 have a normal
hite blood cell count of 4.0  109/L. Of these 38
atients, 25 are known to be red blood cell transfusion
ndependent, and transfusion data are not available on
he remaining 13 patients.
Causes of death. Twenty-three (38%) of 61 patients
ied after transplantation. Of these, 11 died within the
rst 100 days after transplantation; the probability of
ortality at 100 days after transplantation was 18%
95% CI, 10%-29%). Causes of death are shown in
able 5.
ISCUSSION
This study describes long-term outcomes of pa-
ients with DBA after allogeneic BMT. The relatively
arge patient number, unselected nature of the group,
nd multicenter and multinational origin of study sub-
ects strengthen the conclusions of the study. The
6% (95% CI, 59%-86%) 3- year survival of HLA-
dentical sibling donor transplant recipients in our
tudy is similar to the 66% to 87% reported in the
iterature [8,20,21]. In general, more favorable out-
omes were seen in patients with a better performance
tatus at the time of transplantation and in recipients
f matched sibling donor transplants.
We found a 9% incidence of nonengraftment.
his is similar to that seen in similar nonmalignant
ematologic disorders such as thalassemia, aplastic
nemia, and sickle cell disease, in which an approxi-
ately 10% risk of graft failure has been reported
28,29]. The number of transfusions before transplan-
ation was signiﬁcantly correlated with the speed of
eutrophil and platelet recovery. Patients who re-
eived 50 transfusions before transplantation were
ore likely to have neutrophil recovery by day 28 and
latelet recovery by day 60 than patients who received
50 transfusions. However, this did not affect survival
data not shown).
In patients with thalassemia, improved outcomes
ave been shown when transplantation is performed at
younger age, before multiple transfusions lead to
ron overload. The number of patients in our study was
oo small to evaluate this possibility. Even though we did
ot ﬁnd a correlation between more transfusions and
urvival, iatrogenic iron overloadmight have contributed
o performance status deterioration. Moreover, we do
ot have data on serum ferritin. A large sample that
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Bncludes a cohort of untransfused patients before trans-
lantation is required to speciﬁcally evaluate the effect of
ransfusions on survival and engraftment in these pa-
ients. However, such a study is unlikely to occur because
ransplantation is often withheld until patients are refrac-
ory to other therapies, and by that time they are usually
ransfusion dependent. All patients in our series had
eceived prior red blood cell transfusions.
Recipients of alternative donor transplants had
orse survival compared with HLA-identical sibling
onor transplant recipients (76% versus 39%; P 
005). Other studies have also reported similar results
fter alternative donor transplantations (87% versus
4%) [21]. In our series, alternative donor transplant
ecipients were more likely to be older, to have re-
eived a total body irradiation–containing condition-
ng regimen, and to have had a longer time from
igure 1. Probability of overall survival after bone marrow trans-
lantation for Diamond-Blackfan anemia, by Karnofsky perfor-
able 4. Signiﬁcant Variables Associated with Survival among Patient
ransplantation for Diamond-Blackfan Anemia
End Point No. Evaluated
00-d survival
Karnofsky/Lansky score
>90 41
<90 19
Type of donor
HLA-identical sibling 41
Other 20
verall survival at 1 y
Karnofsky/Lansky score
>90 41
<90 19
Type of donor
HLA-identical sibling 41
Other 20
verall survival at 3 y
Karnofsky/Lansky score
<90 19
>90 41
Type of donor
HLA-identical sibling 41
Other 20
I indicates conﬁdence interval.
Survival was calculated by using the Kaplan-Meier product-limit e
Pointwise P value.ance score (KPS) before transplantation. p
B & M Tiagnosis to transplantation. These factors may have
ontributed to the worse outcome of these patients.
Potential related donors may require additional
valuation because some cases initially thought to
e sporadic were later deemed familial DBA [30].
n increased erythrocyte amine deaminase, fetal
emoglobin level, or macrocytosis may be the only
henotypic abnormality in the siblings [31]. Even
ore disconcerting is that obligate heterozygotes
ay exhibit a completely silent phenotype [32]. The
onsequence of using such a sibling as a donor is
nknown. A single report described a DBA patient
ho did not engraft after receiving a graft from his
ister, who had high serum levels of erythrocyte
mine deaminase [33]. Although the rate of nonen-
raftment in our series is not high and is similar to
hat with other nonmalignant hematologic disor-
ers, we cannot be certain whether any instances
igure 2. Probability of overall survival after bone marrow trans-
nderwent Allogeneic Bone Marrow or Peripheral Blood
Probability (95% CI)* P Value†
<.001
93 (79–98)
63 (38–80)
.120
88 (73–95)
70 (45–85)
.020
78 (62–88)
47 (24–67)
.010
78 (62–88)
45 (23–65)
.011
42 (20–62)
75 (59–86)
.005
76 (59–86)
39 (19–60)
.s Who U
stimatelantation for Diamond-Blackfan anemia, by type of donor.
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6ould be attributed to the use of an affected donor.
his suggests that caution should be exercised in
election of a related donor. Related donors should
e evaluated for erythrocyte amine deaminase, fetal
emoglobin, macrocytosis, and physical abnormal-
ties consistent with DBA. RPS19 mutation analysis
hould be performed in all DBA patients, and, when
ositive, their prospective donors should be evalu-
ted to ensure absence of the mutation.
With a median follow-up of 10 years, these pa-
ients had Karnofsky performance scores of 90 or 100.
ven though performance status is at best a rough
easure of quality of life, these scores suggest that
ong-term survivors do not experience excess morbid-
ty after transplantation. In addition, engraftment has
een sustained in surviving patients, thus indicating a
ood hematologic response to transplantation. None
f these patients was reported to have developed a
alignancy after transplantation.
All patients except 1 in this series received con-
entional, cyclophosphamide-based conditioning
egimens. Nonmyeloablative or reduced-intensity
onditioning regimens may decrease transplant-re-
ated morbidity and mortality, but this remains to
e proven. Case reports of successful nonmyeloab-
ative transplantations in DBA are encouraging
34,35], but further studies with larger patient num-
ers are needed to critically evaluate its role. We
onclude that allogeneic BMT can result in long-
erm survival for patients with DBA. Early trans-
lantation before patients develop transfusion-re-
ated iron overload or other comorbidities might
mprove outcomes. Although HLA-matched sibling
onors are generally preferred over alternative do-
ors, one must remain alert to the possibility of
iblings with a hematologically silent DBA pheno-
ype [33]. Unrelated donor transplants should be
able 5. Causes of Death among Patients Who Underwent Allogeneic
ransplantation for Diamond-Blackfan Anemia (n  23)
Cause of Death n (%)
raft failure 6 (27)
VHD 1 (4)
nterstitial pneumonia 3 (13)
nfection 7 (31)
rgan failure 2 (9)
emorrhage 1 (4)
erebral infarction 1 (4)
eizures and hypoxia 1 (4)
ther 1 (4)
VHD indicates graft-versus-host disease.
he causes of death for the ﬁrst 100 days were graft failure (n  4),
GVHD (n  1), interstitial pneumonia (n  3), organ failure (n
 1), hemorrhage (n  1), and seizures and hypoxia (n  1).onsidered in selected patients. R
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PPENDIX 1
In addition to the authors, other members of the
nternational Bone Marrow Transplant Registry
orking Committee on Non-Malignant Marrow
isorders who participated in the study included the
ollowing: S.E. Ball, MD, St. George’s Hospital Med-
cal School, London, United Kingdom; B.M. Camitta,
D, Medical College of Wisconsin, Milwaukee, WI;
.P. Gale, MD, PhD, Center for Advanced Studies in
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Beukemia, Los Angeles, CA; T.G. Gross, MD, PhD,
olumbus Children’s Hospital, Columbus, OH; G.A.
ale, MD, St. Jude Children’s Research Hospital,
emphis, TN; J.T. Horan, MD, University of Roch-
ster Medical Center, Rochester, NY; J.M. Lipton,
D, PhD, Schneider Children’s Hospital, New Hyde
ark, NY; C.M. Niemeyer, MD, Universitats-Kinder-
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